Bancroft Robert E. 4

What Happened
Robert E. Bancroft, President, CEO and a director of AEON Biopharma, was granted 3,000,000 restricted stock units (RSUs) on February 17, 2026. The Form 4 reports the acquisition at $0.00 per unit (total reported value $0), reflecting an award of RSUs rather than a cash purchase. This is a grant (transaction code A), not a sale or market purchase.

Key Details

• Transaction date: 2026-02-17; Form 4 filed 2026-02-19 (timely filing).
• Transaction type/code: Award/Grant (A).
• Units granted: 3,000,000 restricted stock units; reported acquisition price $0.00 (total $0 on Form 4).
• Vesting: Per footnote F1, the RSUs vest in substantially equal installments on each of the first, second, third and fourth anniversaries of the Feb 17, 2026 grant date, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing.
• No additional notes on 10b5-1 plan, tax withholding, or immediate sale were reported.

Context
RSUs are a grant that convert to actual shares (and typically create taxable income) only as they vest; they are not an immediate market purchase or sale. Awards like this are generally part of executive compensation/retention programs and do not by themselves indicate an insider buying or selling shares in the open market.